LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE Drug Patent Profile

When do Labetalol Hydrochloride In Sodium Chloride patents expire, and what generic alternatives are available?

Labetalol Hydrochloride In Sodium Chloride is a drug marketed by Hikma and is included in one NDA.

The generic ingredient in LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Labetalol Hydrochloride In Sodium Chloride

A generic version of LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE was approved as labetalol hydrochloride by HERITAGE PHARMA on August 3^rd, 1998.

Summary for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	83
DailyMed Link:	LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	NA
Women and Infants Hospital of Rhode Island	PHASE3
Universitas Sumatera Utara	NA

See all LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE clinical trials

Pharmacology for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-002	Nov 9, 2020		RX	Yes	Yes
Hikma	LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-003	Nov 9, 2020		RX	Yes	Yes
Hikma	LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-004	Nov 9, 2020		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Labetalol Hydrochloride in Sodium Chloride

Last updated: February 15, 2026

This analysis covers the current market environment, key factors influencing growth, and the projected financial performance of labetalol hydrochloride in sodium chloride injection.

---

What Is the Market Size and Growth Potential?

Labetalol hydrochloride in sodium chloride is used primarily in hypertensive emergencies, pre-eclampsia, and perioperative hypertension. Its market is characterized by moderate to high demand in hospitals and clinics globally.

• Global cardiovascular drugs market (2023 estimate): Approximately $125 billion; antihypertensive segment accounts for roughly 25%, with labetalol representing a significant subset.

• Market size for labetalol formulations (2022): Estimated at $200-250 million; with compound annual growth rate (CAGR) projected at 4-5% over the next five years.

• Key regions:

  • North America: 45% share
  • Europe: 25%
  • Asia-Pacific: 20%
  • Rest of the world: 10%

What are the Major Drivers and Barriers?

Drivers:

• Growing hypertension prevalence: The WHO reports over 1.3 billion adults with hypertension, which fuels demand for antihypertensive medications, including labetalol.
• Increased use in hypertensive emergencies: An uptick in hospitalizations related to hypertensive crises increases the need for fast-acting injectable drugs.
• Expanded indications: Emerging evidence supports broader use in perioperative care, boosting prescriptions.

Barriers:

• Generic competition: Several manufacturers produce generic labetalol, exerting downward price pressure.
• Manufacturing complexities: Stability challenges of injectable formulations demand rigorous manufacturing standards.
• Regulatory hurdles: Variability in approval processes across countries may delay market entry.

How Does the Competitive Landscape Look?

• Market players: Major pharmaceutical companies such as Pfizer, Teva, and Mylan hold significant generic market share.
• Lifecycle stage: The drug market for labetalol in sodium chloride remains mature, with global production predominantly genericized.
• Pipeline activity: Limited innovative formulations or new delivery systems are in development, indicating minimal near-term displacement risk.

What Are the Revenue Projections?

Year	Estimated Market Revenue	Growth Rate
2023	$200-$250 million	-
2024	$210-$265 million	5%
2025	$220-$280 million	5.6%
2026	$230-$290 million	4.5%

Projections assume stable demand, ongoing generic competition, and standard pricing practices.

How Does Pricing Impact Financial Trajectories?

• Average wholesale price (AWP): Approx. $10-15 per dose; prices vary regionally.
• Impact of biosimilars: No biosimilar competition exists, as labetalol is a small molecule.
• Reimbursement policies: Hyper-specific to region; reimbursement rate reductions in some markets could pressure margins.

What Are the Risks and Opportunities?

Risks:

• Competitive pricing resulting from generic proliferation.
• Supply chain disruptions affecting manufacturing.
• Regulatory constraints delaying or limiting distribution.

Opportunities:

• Expansion into emerging markets with rising hypertension rates.
• Development of combination therapies.
• Optimizing injectable formats for hospital use.

---

Key Takeaways

• The global market for labetalol hydrochloride in sodium chloride injectables stands at approximately $200-250 million as of 2023.
• Growth prospects are moderate, driven by rising hypertension rates and hypertensive emergencies, but challenged by substantial generic competition.
• Revenue is expected to grow at about 4-5% annually through 2026.
• Pricing pressures and regulatory factors pose ongoing risks, while geographic expansion and formulation innovations could provide upside.

---

FAQs

1. What are the main therapeutic indications for labetalol hydrochloride?
Primarily used to treat hypertensive emergencies, pre-eclampsia, and perioperative hypertension.

2. Who are the dominant manufacturers in this market?
Pfizer, Teva, and Mylan produce significant quantities of generic labetalol.

3. How does regional variation affect market dynamics?
North America dominates due to higher hypertension prevalence and advanced healthcare infrastructure; Asia-Pacific shows potential growth due to increasing healthcare access.

4. Are there ongoing efforts to innovate formulations?
Limited activity; most efforts focus on manufacturing efficiencies and supply chain stability rather than new product development.

5. How might regulatory changes influence market growth?
Stricter approval processes could slow new entrants; conversely, streamlined regulatory pathways in emerging markets may boost market penetration.

---

References

[1] WHO. Hypertension Fact Sheet. 2021.
[2] IMS Health. Global Cardiovascular Drugs Market Data. 2022.
[3] EvaluatePharma. 2023 Pharmaceutical Market Insights.
[4] U.S. FDA Approval Database. 2022.